dc.creator | Trujillo-Rodriguez, Maria | es |
dc.creator | Muñoz Muela, Esperanza | es |
dc.creator | Serna Gallego, Ana | es |
dc.creator | Praena Fernández, Juan Manuel | es |
dc.creator | Pérez Gómez, Alberto | es |
dc.creator | Gasca-Capote, Carmen | es |
dc.creator | López Cortés, Luis Fernando | es |
dc.date.accessioned | 2023-05-25T13:50:10Z | |
dc.date.available | 2023-05-25T13:50:10Z | |
dc.date.issued | 2022-07-14 | |
dc.identifier.citation | Trujillo-Rodriguez, M., Muñoz Muela, E., Serna Gallego, A., Praena Fernández, J.M., Pérez Gómez, A., Gasca-Capote, C. y López Cortés, L.F. (2022). Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients. PLoS ONE, 17 (7), e0269875. https://doi.org/10.1371/journal.pone.0269875. | |
dc.identifier.issn | 1932-6203 | es |
dc.identifier.uri | https://hdl.handle.net/11441/146631 | |
dc.description.abstract | Background
The SARS-CoV-2 pandemic has overwhelmed hospital services due to the rapid transmission of the virus and its severity in a high percentage of cases. Having tools to predict which patients can be safely early discharged would help to improve this situation.
Methods
Patients confirmed as SARS-CoV-2 infection from four Spanish hospitals. Clinical, demographic, laboratory data and plasma samples were collected at admission. The patients were classified into mild and severe/critical groups according to 4-point ordinal categories based on oxygen therapy requirements. Logistic regression models were performed in mild patients with only clinical and routine laboratory parameters and adding plasma pro-inflammatory cytokine levels to predict both early discharge and worsening.
Results
333 patients were included. At admission, 307 patients were classified as mild patients. Age, oxygen saturation, Lactate Dehydrogenase, D-dimers, neutrophil-lymphocyte ratio (NLR), and oral corticosteroids treatment were predictors of early discharge (area under curve (AUC), 0.786; sensitivity (SE) 68.5%; specificity (S), 74.5%; positive predictive value (PPV), 74.4%; and negative predictive value (NPV), 68.9%). When cytokines were included, lower interferon-γ-inducible protein 10 and higher Interleukin 1 beta levels were associated with early discharge (AUC, 0.819; SE, 91.7%; S, 56.6%; PPV, 69.3%; and NPV, 86.5%). The model to predict worsening included male sex, oxygen saturation, no corticosteroids treatment, C-reactive protein and Nod-like receptor as independent factors (AUC, 0.903; SE, 97.1%; S, 68.8%; PPV, 30.4%; and NPV, 99.4%). The model was slightly improved by including the determinations of interleukine-8, Macrophage inflammatory protein-1 beta and soluble IL-2Rα (CD25) (AUC, 0.952; SE, 97.1%; S, 98.1%; PPV, 82.7%; and NPV, 99.6%).
Conclusions
Clinical and routine laboratory data at admission strongly predict non-worsening during the first two weeks; therefore, these variables could help identify those patients who do not need a long hospitalization and improve hospital overcrowding. Determination of pro-inflammatory cytokines moderately improves these predictive capacities. | es |
dc.format | application/pdf | es |
dc.format.extent | 15 p. | es |
dc.language.iso | eng | es |
dc.publisher | Public Library of Science | es |
dc.relation.ispartof | PLoS ONE, 17 (7), e0269875. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Clinical, laboratory data and inflammatory biomarkers at baseline as early discharge predictors in hospitalized SARS-CoV-2 infected patients | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | RH-0037-2020 a JV | es |
dc.relation.projectID | PY20/01276 a APG | es |
dc.relation.projectID | CP19/00159 a AGV | es |
dc.relation.projectID | CP19/00146 a AR | es |
dc.relation.projectID | FI19/00304 a EMM | es |
dc.relation.projectID | FI19/00083 | es |
dc.relation.projectID | MCGC,RD16/0025/0020 | es |
dc.relation.projectID | RD16/0025/0006 | es |
dc.relation.projectID | RD16/0025/0026 | es |
dc.relation.projectID | CB21/13/00020 | es |
dc.relation.publisherversion | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0269875 | es |
dc.identifier.doi | 10.1371/journal.pone.0269875 | es |
dc.journaltitle | PLoS ONE | es |
dc.publication.volumen | 17 | es |
dc.publication.issue | 7 | es |
dc.publication.initialPage | e0269875 | es |
dc.contributor.funder | Consejería de Salud y Familia | es |
dc.contributor.funder | Consejería de Transformación Económica, Industria, Conocimiento y Universidades | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |